Celecoxib versus mefenamic acid in the treatment of primary dysmenorrhea
-
Nurul Iftida Basri
,
Nur Azurah Abd Ghani
Abstract
Background
The objective was to compare the effectiveness and tolerability of mefenamic acid and celecoxib in women with primary dysmenorrhea (PD) and to compare the quality of life of study participants pre- and post-treatment.
Materials and methods
This was a randomized crossover clinical trial conducted among sexually inactive female adults aged 18–25 years with PD. Participants were asked to rate their pain score and answer a validated quality of life questionnaire (EQ-5D-3L) before and after consumption of each medication in two menstrual cycles. The effectiveness of celecoxib and mefenamic acid in treating PD was compared with regard to reduction in pain score and the need for medical leave and rescue therapy. Drug tolerability was determined by comparing the occurrence of side effects of both drugs. Quality of life scores pre- and post-intervention were measured and compared.
Results
Mefenamic acid had a comparable effect to celecoxib in relieving symptoms of PD. Both drugs were equally tolerable and showed similar impacts on quality of life.
Conclusions
This study demonstrated that mefenamic acid and celecoxib had similar effectiveness in improving pain score and quality of life in women with PD.
Author statement
Research funding: Funding was obtained from the Medical Research and Committee UKMMC. The committee had no role in the collection, analysis, data interpretation, writing of report and decision to submit this article for publication.
Conflict of interest: The authors declared no conflicts of interest.
Informed consent: Informed consent was obtained prior to research.
Ethical approval: This has been approved by the Medical Research and Ethics Committee UKMMC (Research Code: FF-2016-204).
References
[1] Shamsunarnie MZ, Lin N, Tengku Norbanee TH, Nik Hazlina N. Primary dysmenorrhea among medical and dental university students in kelantan: prevalence and associated factors. Int Med J. 2009;16:93–9.Search in Google Scholar
[2] Nor Azlin MI, Maryasalwati I, Norzilawati MN, Mahdy ZA, Jamil MA, Zainul Rashid MR. The efficacy of etoricoxib vs mefenamic acid in the treatment of primary dysmenorrhea: a randomized comparative trial. J Obstet Gynaecol. 2008;28:424–6.10.1080/01443610802150051Search in Google Scholar PubMed
[3] Ali Z, Burnett I, Eccles R, North M, Jawad M, Jawad S, et al. Efficacy of paracetamol and caffeine combination in the treatment of the key symptoms of primary dysmenorrhea. Curr Med Res Opin. 2007;23:841–51.10.1185/030079907X182239Search in Google Scholar PubMed
[4] Azagew AW, Kassie DG, Walle TA. Prevalence of primary dysmenorrhea, its intensity, impact and associated factors among female students’ at Gondar town preparatory school, Northwest Ethiopia. BMC Womens Health. 2020;20:5.10.1186/s12905-019-0873-4Search in Google Scholar PubMed PubMed Central
[5] Maurício PA, Pérsio YA, Paulo FR, Ricardo S. Guidelines in focus. Primary dysmenorrhea treatment. Rev Assoc Med Bras. 2013;59:413–9.10.1016/j.ramb.2012.05.001Search in Google Scholar PubMed
[6] Ragia H, Mohamed A, Madiha A. Cardiorenal effects of newer NSAIDs (Celecoxib) versus classic NSAIDs (Ibuprofen) in patients with arthritis. J Toxicol. 2011;86:2153–8.10.1155/2011/862153Search in Google Scholar
[7] Salo DF, Lavery R, Varma V, Goldberg J, Shapiro T, Kenwood A. A randomized clinical trial comparing oral Celecoxib 200 mg, Celecoxib 400 mg, and Ibuprofen 600 mg for acute pain. Acad Emerg Med. 2003;10:22–30.10.1197/aemj.10.1.22Search in Google Scholar
[8] Heidarifar R, Mehran N, Heidari A, Tehran HA, Koohbor M, Mansourabad MK. Effect of dill (Anethum graveolens) on the severity of primary dysmenorrhea in compared with mefenamic acid: a randomized, double-blind trial. J Res Med Sci. 2014;19:326–30.Search in Google Scholar
[9] Daniels S, Robbins J, West CR, Nemeth MA. Celecoxib in the treatment of primary dysmenorrhea: results from two randomized, double-blind, active- and placebo-controlled, crossover studies. Clin Ther. 2009;31:1192–208.10.1016/j.clinthera.2009.06.003Search in Google Scholar PubMed
[10] Giti O, Marjan G, Fariborz M. Comparison of effects of ginger, mefenamic acid and ibuprofen on pain in women with primary dysmenorrhea. J Altern Complement Med. 2009;15:129–32.10.1089/acm.2008.0311Search in Google Scholar PubMed
[11] Camlibel M, Erdur B, Yilmaz A, Ozen M, Uyanik A. Comparison of the effects of piroxicam and diclofenac sodium as treatments for primary dysmenorrhea. Med Sci Monit. 2019;25:157–6410.12659/MSM.911711Search in Google Scholar PubMed PubMed Central
[12] Dolan P. Modelling valuation for EuroQol health states. Med Care. 1997;35:1095–108.10.1097/00005650-199711000-00002Search in Google Scholar PubMed
[13] Stella I, Ingrid A, Fiona CB. What we know about primary dysmenorrhea today: a critical review. Hum Reprod Update. 2015;21:762–7810.1093/humupd/dmv039Search in Google Scholar PubMed
[14] Campbell MA, McGrath PJ. Use of medication by adolescents for the management of menstrual discomfort. Archi Pediatr Adolesc Med. 1997;151:905–13.10.1001/archpedi.1997.02170460043007Search in Google Scholar PubMed
[15] Marjoribanks J, Ayeleke RO, Farquhar C, Proctor M. Nonsteroidal anti-inflammatory drugs for dysmenorrhea. Cochrane Database Syst Rev. 2015;7:CD001751.10.1002/14651858.CD001751.pub3Search in Google Scholar PubMed PubMed Central
[16] De Mello NR, Baracat EC, Tomaz G, Bedone AJ, Camargos A, Barbosa IC, et al. Double-blind study to evaluate efficacy and safety of meloxicam 7.5 mg and 15 mg versus mefenamic acid 1500 mg in the treatment of primary dysmenorrhea. Acta Obstetricia et Gynecologica Scandinavica. 2004;83:667–73.10.1111/j.0001-6349.2004.00433.xSearch in Google Scholar PubMed
[17] Anil P, Nitin BC, Rajashree TP, Swati NA, Rajini BU, Sanjay Kumar GT. Efficacy and safety of aceclofenac and drotaverine fixed-dose combination in the treatment of primary dysmenorrhoea: a double-blind, double-dummy, randomized comparative study with aceclofenac. Eur J Obstet Gynecol Reprod Biol. 2010;152:86–90.10.1016/j.ejogrb.2010.05.007Search in Google Scholar PubMed
[18] Anna L, Daniel SS. Role of non-steroidal anti-inflammatory drugs in gynecology. Pharmaceuticals. 2010;3:2082–9.10.3390/ph3072082Search in Google Scholar PubMed PubMed Central
Supplementary Material
The online version of this article offers supplementary material (DOI: https://doi.org/10.1515/hmbci-2019-0069).
© 2020 Walter de Gruyter GmbH, Berlin/Boston
Articles in the same Issue
- Special Section: "Update in the management of ovarian cancer"; Guest Editors: René Druckmann and Adolf E. Schindler
- Editorial
- Preface to special issue: update in the management of ovarian cancer
- Original Article
- Ovarian cancer screening in the general population
- Review Articles
- Non-surgical prevention strategies in women with hereditary breast and ovarian cancer syndromes
- Hyperthermic intraperitoneal chemotherapy in ovarian cancer: an update
- Genetic testing in ovarian cancer – clinical impact and current practices
- The place of secondary complete cytoreductive surgery in advanced ovarian cancer
- An update on preoperative assessment of the resectability of advanced ovarian cancer
- Impact of retroperitoneal lymph node dissection in ovarian cancer – time for paradigm shift?
- Minireviews
- Ultrasound screening of ovarian cancer
- How to manage BRCA mutation carriers?
- Regular Issue
- Original Articles
- Progestogen addition with low-dose levonorgestrel intrauterine system in menopausal hormone treatment gives less normal breast tissue proliferation than oral norethisterone acetate or medroxyprogesterone acetate
- The effectiveness of military physical exercise on irisin concentrations and oxidative stress among male healthy volunteers
- Periodontal status and bone metabolism in women in reproductive and postmenopausal periods
- Modulatory effect of tropisetron in the liver of streptozotocin-induced diabetes in rats: biochemical and histological evidence
- Celecoxib versus mefenamic acid in the treatment of primary dysmenorrhea
- The predictive role of amylase and lipase levels on pancreas injury diagnosis in patients with blunt abdominal trauma
- Case Report
- Low hormone levels during an attack of systemic capillary leak syndrome normalizing after treatment
Articles in the same Issue
- Special Section: "Update in the management of ovarian cancer"; Guest Editors: René Druckmann and Adolf E. Schindler
- Editorial
- Preface to special issue: update in the management of ovarian cancer
- Original Article
- Ovarian cancer screening in the general population
- Review Articles
- Non-surgical prevention strategies in women with hereditary breast and ovarian cancer syndromes
- Hyperthermic intraperitoneal chemotherapy in ovarian cancer: an update
- Genetic testing in ovarian cancer – clinical impact and current practices
- The place of secondary complete cytoreductive surgery in advanced ovarian cancer
- An update on preoperative assessment of the resectability of advanced ovarian cancer
- Impact of retroperitoneal lymph node dissection in ovarian cancer – time for paradigm shift?
- Minireviews
- Ultrasound screening of ovarian cancer
- How to manage BRCA mutation carriers?
- Regular Issue
- Original Articles
- Progestogen addition with low-dose levonorgestrel intrauterine system in menopausal hormone treatment gives less normal breast tissue proliferation than oral norethisterone acetate or medroxyprogesterone acetate
- The effectiveness of military physical exercise on irisin concentrations and oxidative stress among male healthy volunteers
- Periodontal status and bone metabolism in women in reproductive and postmenopausal periods
- Modulatory effect of tropisetron in the liver of streptozotocin-induced diabetes in rats: biochemical and histological evidence
- Celecoxib versus mefenamic acid in the treatment of primary dysmenorrhea
- The predictive role of amylase and lipase levels on pancreas injury diagnosis in patients with blunt abdominal trauma
- Case Report
- Low hormone levels during an attack of systemic capillary leak syndrome normalizing after treatment
